This is the authors' abstract. We don't add key points for this paper.
Treatment options for advanced synovial sarcoma that has progressed beyond first-line therapy are severely scarce. This prospective, single-center, phase II Simon clinical trial evaluated high-dose ifosfamide 11 g/m² administered over 4 days every 21 days with mesna, prophylactic growth factors, and albumin supplementation for up to 6 cycles to determine an optimal regimen balancing efficacy, toxicity, and quality of life (QoL). Eligible participants were aged ≥ 16 years with metastatic or unresectable synovial sarcoma, measurable disease per RECIST v1.1, ECOG performance status 0–2, and progression after at least one prior line of therapy. Prior ifosfamide exposure was permitted. Among 26 enrolled (median age: 30), 22 were evaluable for response. 35% had ECOG performance status 2. The ORR was 63.6%. Median PFS was 7.5 months (95% CI, 5.9–9.4), and median OS was not reached at median follow-up of 12 months. Greater number of prior treatment lines was independently associated with inferior PFS (hazard ratio, 4.83; 95% CI, 1.40–16.64). Grade 3 or higher treatment-related adverse events occurred in 77% of patients. Treatment discontinuation due to toxicity occurred in 15% of the patients. QoL analysis demonstrated significant declines in global health status and functional domains, despite improvements in pain and dyspnea. High-dose ifosfamide at 11 g/m² demonstrated substantial efficacy with durable disease control in advanced synovial sarcoma. While treatment was associated with significant toxicity and QoL deterioration, symptomatic improvement supports its continued role as a key therapeutic option, particularly in the regions where access to cellular therapies is limited.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
R et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: